Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU
Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in
SAN FRANSISCO, CA / ACCESSWIRE /
As Jaguar announced yesterday, the Company has signed a Memorandum of Understanding (the "MOU") with
"Jaguar was previously in discussions with
"Although I was also unable to come to terms with
Per the MOU, the Dragon SPAC has been granted exclusivity to negotiate and finalize the documentation for the contemplated merger transaction with Napo EU and to list the combined entity on AIM Italia.
As previously announced, the Company is exploring the conditional marketing authorization regulatory pathway in
Mytesi (crofelemer delayed release tablets), the only oral plant-based prescription medicine approved under
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Napo EU will be the named target of the Dragon SPAC, the expectation that the Dragon SPAC will list on AIM Italia, and the belief that crofelemer's mechanism of action has the potential to benefit multiple disorders. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.